Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Lenhard, Miriam ^a   Tsvilina, Alexandra ^a   Schumacher, Lan ^a   Kupka, Markus ^a   Ditsch, Nina ^a   Mayr, Doris ^a   Friese, Klaus ^a   Jeschke, Udo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

HCG; LH receptor; Ovarian cancer; Prognosis

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN RECEPTOR; LUTEINIZING HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HUMAN CHORIONIC GONADOTROPIN BLOOD LEVEL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MUCINOUS OVARIAN CARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHORIONIC GONADOTROPIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; YOUNG ADULT;

EID: 84855253240     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-2     Document Type: Article

References (52)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993, 329(21):1550-1559. 10.1056/NEJM199311183292108, 8155119.
2. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999, 10(Suppl 1):3-7.
3. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991, 9(7):1138-1150.
4. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993, 71(4 Suppl):1559-1564.
5. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004, 83(9):783-795.
6. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998, 90(23):1774-1786. 10.1093/jnci/90.23.1774, 9839517.
7. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994, 331(12):771-776. 10.1056/NEJM199409223311204, 8065405.
8. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002, 155(3):217-224. 10.1093/aje/155.3.217, 11821246.
9. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992, 136(10):1212-1220.
10. Jeschke U, Toth B, Scholz C, Friese K, Makrigiannakis A. Glycoprotein and carbohydrate binding protein expression in the placenta in early pregnancy loss. J Reprod Immunol 2010, 85(1):99-105. 10.1016/j.jri.2009.10.012, 20299109.
11. Hoshina M, Hussa R, Pattillo R, Camel HM, Boime I. The role of trophoblast differentiation in the control of the hCG and hPL genes. Adv Exp Med Biol 1984, 176:299-312.
12. Policastro PF, Daniels-McQueen S, Carle G, Boime I. A map of the hCG beta-LH beta gene cluster. J Biol Chem 1986, 261(13):5907-5916.
13. Jeschke U, Stahn R, Goletz C, Wang X, Briese V, Friese K. hCG in trophoblast tumour cells of the cell line Jeg3 and hCG isolated from amniotic fluid and serum of pregnant women carry oligosaccharides of the sialyl Lewis × and sialyl Lewis a type. Anticancer Res 2003, 23(2A):1087-1092.
14. Cole LA, Hartle RJ, Laferla JJ, Ruddon RW. Detection of the free beta subunit of human chorionic gonadotropin (HCG) in cultures of normal and malignant trophoblast cells, pregnancy sera, and sera of patients with choriocarcinoma. Endocrinology 1983, 113(3):1176-1178. 10.1210/endo-113-3-1176, 6191970.
15. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000, 76(1):80-88. 10.1006/gyno.1999.5628, 10620446.
16. Minegishi T, Kameda T, Hirakawa T, Abe K, Tano M, Ibuki Y. Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin Cancer Res 2000, 6(7):2764-2770.
17. Lenhard M, Lennerova T, Ditsch N, Kahlert S, Friese K, Mayr D, Jeschke U. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 2011, 58(6):990-994. 10.1111/j.1365-2559.2011.03848.x, 21585434.
18. Jeschke U, Walzel H, Mylonas I, Papadopoulos P, Shabani N, Kuhn C, Schulze S, Friese K, Karsten U, Anz D, et al. The human endometrium expresses the glycoprotein mucin-1 and shows positive correlation for Thomsen-Friedenreich epitope expression and galectin-1 binding. J Histochem Cytochem 2009, 57(9):871-881. 10.1369/jhc.2009.952085, 2728131, 19506091.
19. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kunze S, Dian D, Friedl C, Kupka MS, Friese K. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 2007, 22(2):169-176.
20. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8(3):138-140.
21. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev 2007, 28(4):440-461. 10.1210/er.2006-0036, 17463396.
22. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983, 71(4):717-721.
23. Vanderhyden BC. Loss of ovarian function and the risk of ovarian cancer. Cell Tissue Res 2005, 322(1):117-124. 10.1007/s00441-005-1100-1, 15902502.
24. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004, 191(3):733-740. 10.1016/j.ajog.2004.03.035, 15467532.
25. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007, 13(2):143-162.
26. Jernstrom H, Borg K, Olsson H. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. Mol Genet Metab 2005, 86(1-2):320-327. 10.1016/j.ymgme.2005.06.007, 16084122.
27. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer-a short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007, 269(1-2):61-64. 10.1016/j.mce.2006.11.014, 17353087.
28. Chen FC, Oskay-Ozcelik G, Buhling KJ, Kopstein U, Mentze M, Lichtenegger W, Sehouli J. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res 2009, 29(5):1575-1578.
29. Alfthan H, Haglund C, Dabek J, Stenman UH. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem 1992, 38(10):1981-1987.
30. Stenman UH, Alfthan H, Ranta T, Vartiainen E, Jalkanen J, Seppala M. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab 1987, 64(4):730-736. 10.1210/jcem-64-4-730, 3546353.
31. Vaitukaitis JL. Human chorionic gonadotropin as a tumor marker. Ann Clin Lab Sci 1974, 4(4):276-280.
32. Rutanen EM, Seppala M. The hCG-beta subunit radioimmunoassay in nontrophoblastic gynecologic tumors. Cancer 1978, 41(2):692-696. 10.1002/1097-0142(197802)41:2<692::AID-CNCR2820410239>3.0.CO;2-B, 630545.
33. Samaan NA, Smith JP, Rutledge FN, Schultz PN. The significance of measurement of human placental lactogen, human chorionic gonadotropin, and carcinoembryonic antigen in patients with ovarian carcinoma. Am J Obstet Gynecol 1976, 126(2):186-189.
34. Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH, Chard T. The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix. Gynecol Oncol 1994, 55(2):271-276. 10.1006/gyno.1994.1289, 7525427.
35. Grossmann M, Hoermann R, Gocze PM, Ott M, Berger P, Mann K. Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies. Eur J Clin Invest 1995, 25(11):867-873. 10.1111/j.1365-2362.1995.tb01697.x, 8582453.
36. Guo X, Liu G, Schauer IG, Yang G, Mercado-Uribe I, Yang F, Zhang S, He Y, Liu J. Overexpression of the beta subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol 2011, 179(3):1385-1393. 10.1016/j.ajpath.2011.05.018, 21763678.
37. Wurzel RS, Yamase HT, Nieh PT. Ectopic production of human chorionic gonadotropin by poorly differentiated transitional cell tumors of the urinary tract. J Urol 1987, 137(3):502-504.
38. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002, 87(11):5290-5296. 10.1210/jc.2002-020642, 12414904.
39. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, Chard T. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996, 77(1):61-69. 10.1046/j.1464-410X.1996.82910.x, 8653319.
40. Huang CF, Liu DY, Shen K. Follicle stimulating hormone inhibits cisplatin induced apoptosis in ovarian cancer cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003, 25(4):447-450.
41. Abdallah MA, Lei ZM, Li X, Greenwold N, Nakajima ST, Jauniaux E. Rao Ch V: Human fetal nongonadal tissues contain human chorionic gonadotropin/luteinizing hormone receptors. J Clin Endocrinol Metab 2004, 89(2):952-956. 10.1210/jc.2003-030917, 14764820.
42. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990, 70(2):421-430. 10.1210/jcem-70-2-421, 1688865.
43. Tao YX, Lei ZM, Rao CV. The presence of luteinizing hormone/human chorionic gonadotropin receptors in lactating rat mammary glands. Life Sci 1997, 60(15):1297-1303. 10.1016/S0024-3205(97)00073-8, 9096247.
44. Zhang M, Shi H, Segaloff DL, Van Voorhis BJ. Expression and localization of luteinizing hormone receptor in the female mouse reproductive tract. Biol Reprod 2001, 64(1):179-187.
45. Lin PC, Li X, Lei ZM. Rao Ch V: Human cervix contains functional luteinizing hormone/human chorionic gonadotropin receptors. J Clin Endocrinol Metab 2003, 88(7):3409-3414. 10.1210/jc.2002-021966, 12843195.
46. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003, 78(1):17-27. 10.1023/A:1022169525521, 12611453.
47. Rahman NA, Rao CV. Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research. Mol Hum Reprod 2009, 15(1):703-711. 10.1093/molehr/gap067, 19710244.
48. Bodek G, Rahman NA, Zaleska M, Soliymani R, Lankinen H, Hansel W, Huhtaniemi I, Ziecik AJ. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. Breast Cancer Res Treat 2003, 79(1):1-10. 10.1023/A:1023351819956, 12779076.
49. Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ, Rahman NA. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia 2005, 7(5):497-508. 10.1593/neo.04751, 1501163, 15967102.
50. Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol 2002, 85(1):45-52. 10.1006/gyno.2001.6558, 11925119.
51. Gebauer G, Mueller N, Fehm T, Berkholz A, Beck EP, Jaeger W, Licht P. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity. Am J Obstet Gynecol 2004, 190(6):1621-1628. discussion 1628, 10.1016/j.ajog.2004.03.045, 15284756.
52. Gebauer G, Fehm T, Beck EP, Berkholz A, Licht P, Jager W. Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells. Breast Cancer Res Treat 2003, 77(2):125-131. 10.1023/A:1021301001208, 12602911.